Known targets — ChEMBL curated mechanism
ADRB1ADRB2ATP4AATP4BAXLCHRM2CHRM3DRD2FLT3HRH1HTR2AHTR2BHTR2CKCNH2KMT2AMAP2K1MAP2K2MEN1MLNRPLK4RENS1PR1SLC6A2SLC6A4atpAatpBatpCatpDatpEatpFatpFHatpGpol
The experimentally established mechanism targets of Fumaric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 known ✓ | O00255 | 3/20 | 0.65 |
| ▸ | KMT2A known ✓ | Q03164 | 3/20 | 0.65 |
| ▸ | DRD2 known ✓ | P14416 | 2/20 | 0.53 |
| ▸ | CHRM2 known ✓ | P08172 | 2/20 | 0.53 |
| ▸ | CHRM3 known ✓ | P20309 | 2/20 | 0.53 |
| ▸ | HTR2A known ✓ | P28223 | 2/20 | 0.53 |
| ▸ | HTR2C known ✓ | P28335 | 2/20 | 0.53 |
| ▸ | HRH1 known ✓ | P35367 | 2/20 | 0.53 |
| ▸ | HTR2B known ✓ | P41595 | 2/20 | 0.53 |
| ▸ | KCNH2 known ✓ | Q12809 | 1/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.65 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.65 |
| ▸ | LMNA | P02545 | 3/20 | 0.53 |
| ▸ | HTR1A | P08908 | 3/20 | 0.53 |
| ▸ | HTR7 | P34969 | 3/20 | 0.53 |
| ▸ | HTR6 | P50406 | 2/20 | 0.53 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.53 |
| ▸ | CHRM5 | P08912 | 2/20 | 0.53 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.53 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Fumaric Acid SCHEMBL3562688 | 1.00 | KDM4E (0.65) | KDM4EMEN1MAPK1KMT2ALMNA | |
| SCHEMBL905217 | 0.93 | DRD2 (0.60) | KDM4EMEN1MAPK1KMT2ALMNA | |
| SCHEMBL5563082 | 0.84 | HTR2A (0.46) | KDM4EMEN1MAPK1KMT2ALMNA | |
| SCHEMBL5809604 | 0.82 | DRD2 (0.46) | KDM4EMEN1MAPK1KMT2ALMNA | |
| SCHEMBL5329365 | 0.82 | DRD2 (0.46) | KDM4EMEN1MAPK1KMT2ALMNA | |
| SCHEMBL21641980 | 0.79 | ADRA2A (0.54) | KDM4EMEN1MAPK1KMT2ALMNA | |
| Quetiapine SCHEMBL122596 | 0.79 | KDM4E (1.00) | KDM4EMEN1MAPK1KMT2ALMNA | |
| Quetiapine SCHEMBL4962023 | 0.79 | KDM4E (1.00) | KDM4EMEN1MAPK1KMT2ALMNA | |
| Quetiapine SCHEMBL678457 | 0.79 | KDM4E (1.00) | KDM4EMEN1MAPK1KMT2ALMNA | |
| Quetiapine SCHEMBL390694 | 0.79 | KDM4E (1.00) | KDM4EMEN1MAPK1KMT2ALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7687622-B2 | Process for preparing quetiapine fumarate | TEVA PHARMACEUTICAL INDUSTRIES, LTD (IL) | 2010-03-30 | — | — | US | disclosed |
| US-20060276641-A1 | Process for preparing quetiapine fumarate | TEVA PHARMACEUTICAL INDUSTRIES LTD (IL) | 2006-12-07 | — | — | US | disclosed |
| EP-1448169-A1 | METHOD FOR IMPROVING DISSOLUTION OF POORLY DISPERSIBLE MEDICAMENTS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-08-25 | — | — | EP | disclosed |
| EP-1359919-A1 | METHOD OF TREATING SUBSTANCE ABUSE WITH QUETIAPINE | AstraZeneca AB (SE) | 2003-11-12 | — | — | EP | disclosed |
| EP-1345610-A1 | METHOD OF TREATMENT | AstraZeneca AB (SE) | 2003-09-24 | — | — | EP | disclosed |
| EP-1326616-A1 | NEW USE OF QUETIAPINE | AstraZeneca AB (SE) | 2003-07-16 | — | — | EP | disclosed |
| WO-2003039516-A1 | METHOD FOR IMPROVING DISSOLUTION OF POORLY DISPERSIBLE MEDICAMENTS | FUJISAWA PHARMACEUTICLA CO., LTD. (JP) | 2003-05-15 | — | — | WO | disclosed |
| WO-2002062346-A1 | METHOD OF TREATING SUBSTANCE ABUSE WITH QUETIAPINE | ASTRAZENECA AB (SE) | 2002-08-15 | — | — | WO | disclosed |
| EP-1223939-A1 | METHOD OF TREATING WEIGHT GAIN | AstraZeneca AB (SE) | 2002-07-24 | — | — | EP | disclosed |
| WO-2002049652-A1 | METHOD OF TREATMENT | ASTRAZENECA AB (SE) | 2002-06-27 | — | — | WO | disclosed |
| WO-2002020019-A1 | NEW USE OF QUETIAPINE | ASTRAZENECA AB (SE) | 2002-03-14 | — | — | WO | disclosed |
| WO-2000071106-A2 | METHOD OF TREATING WEIGHT GAIN | ASTRAZENECA AB (SE) | 2000-11-30 | — | — | WO | disclosed |
| EP-1000043-A1 | A CRYSTALLINE DIBENZOTHIAZEPINE DERIVATIVE AND ITS USE AS AN ANTIPSYCHOTIC AGENT | AstraZeneca UK Limited (GB) | 2000-05-17 | — | — | EP | disclosed |
| WO-1999006381-A1 | A CRYSTALLINE DIBENZOTHIAZEPINE DERIVATIVE AND ITS USE AS AN ANTIPSYCHOTIC AGENT | ZENECA LIMITED (GB) | 1999-02-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060276641-A1 | Process for preparing quetiapine fumarate | SDHA, SDHB, FH | MEN1 3918/4885KMT2A 230/4885DRD2 626/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.